NOUV — Nouveau Life Pharmaceuticals Share Price
Last trade - 00:00- $0.67m
- $0.99m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.5 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -187.36% | ||
| Return on Equity | -111.38% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008E | 2009E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nouveau Life Pharmaceuticals, Inc. is a Canada-based company, which provides an A Platform for Remote Senior Care. With the NOUV platform, they can monitor all of their patients at a glance. It also provides to monitor details of each patient by just clicking on them. In the case of an emergency, NOUV will detect it before they do. The Company is also focused on its robotic and Ai-based healthcare devices and wearables. Its applications include NOUV Friends - for Seniors, NOUV Guardian - for Individual Personal Users, and NOUV Care Guardian - for Organization. Its subsidiary is Seniorgo.ai.
Directors
- Last Annual
- June 30th, 2007
- Last Interim
- March 31st, 2008
- Incorporated
- May 28th, 1998
- Public Since
- June 21st, 2001
- No. of Shareholders
- 262
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 6,660,963,733
- Address
- 237 Main Street, Box 880, NIVERVILLE, R0A 1E0
- Web
- Phone
- +1 8885502333
- Auditors
- Manning Elliot LLP
Similar to NOUV
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 22:21 UTC, shares in Nouveau Life Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Nouveau Life Pharmaceuticals last closed at $0.00 and the price had moved by -50% over the past 365 days. In terms of relative price strength the Nouveau Life Pharmaceuticals share price has underperformed the S&P500 Index by -53.29% over the past year.
There is no consensus recommendation for this security.
Find out moreNouveau Life Pharmaceuticals does not currently pay a dividend.
Nouveau Life Pharmaceuticals does not currently pay a dividend.
Nouveau Life Pharmaceuticals does not currently pay a dividend.
To buy shares in Nouveau Life Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Nouveau Life Pharmaceuticals had a market capitalisation of $0.67m.
Here are the trading details for Nouveau Life Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NOUV
Based on an overall assessment of its quality, value and momentum Nouveau Life Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nouveau Life Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -48.24%.
As of the last closing price of $0.00, shares in Nouveau Life Pharmaceuticals were trading -25.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nouveau Life Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nouveau Life Pharmaceuticals' management team is headed by:
- Melissa Walker - CEO
- Douglas Dickie - CFO
- Rolly Hein - VPR
- Edward Melenka - DRC